Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On track to dose the first patients in MSS CRC and PROC triple combination proof of concept studies in Q1 2023 and Q2 2023, respectively, with the combination of potential first-in-class anti-PVRIG,
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and pioneer in computational target...
Phase 3 study with rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq:AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902 is expected to start in 2023....
HOLON, Israel, Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. , a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will... | February 13, 2023
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...